Merkel Cell Polyoma Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma by von der Grün, Jens et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Merkel Cell Polyoma Viral Load and Intratumoral CD8+ Lymphocyte
Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma
von der Grün, Jens ; Winkelmann, Ria ; Meissner, Markus ; Wieland, Ulrike ; Silling, Steffi ; Martin,
Daniel ; Fokas, Emmanouil ; Rödel, Claus ; Rödel, Franz ; Balermpas, Panagiotis
Abstract: Introduction: Merkel cell carcinoma (MCC) is linked to the presence of clonally integrated
Merkel cell polyomavirus (MCPyV) in up to 80% of the cases. The aim of the study was to determine
the prognostic value of baseline MCPyV viral load and lymphocytic infiltration. Methods: MCPyV
DNA prevalence, integration status and viral load were determined by specific quantitative real-time
PCR in surgical specimens obtained from 49 patients with MCC treated with (n = 22, 45%) or without
postoperative radiotherapy (RT). CD8+ tumor infiltrating lymphocytes (TILs) and programmed death
ligand 1 (PD-L1) status were assessed using immunohistochemistry. MCPyV characteristics and immune
marker expression were correlated with clinicopathological factors and overall survival (OS). Results:
Median age at diagnosis was 74 (range, 42–100); 51% of the patients were female. One-, three, and
five-year OS rates were 83.8, 58.6, and 47.1%, respectively. A positive MCPyV status was associated
with female gender (p = 0.042). Tumor localization (head/arms vs. trunk) positively correlated with
PD-L1 status (p = 0.011) and combined CD8/PD-L1 expression (p = 0.038). Overall CD8+ infiltration
was inversely associated with N-stage (p = 0.048). Stromal TILs correlated significantly with both
PD-L1 expression (p = 0.010) and N-stage (p = 0.037). A high viral load (>median) was significantly
associated with worse OS (p = 0.029) and high intratumoral CD8+ infiltration with improved OS for
the entire cohort (p = 0.045). Conclusion: These data provide important insight on the role of MCPy
DNA viral load and TILs in the context of PD-L1 in patients with Merkel cell carcinoma. Future clinical
studies should aim to explore the effect of PD-1/PD-L1 immune-checkpoint inhibitors in combination
with existing radiotherapy approaches.
DOI: https://doi.org/10.3389/fonc.2019.00020
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-184285
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
von der Grün, Jens; Winkelmann, Ria; Meissner, Markus; Wieland, Ulrike; Silling, Steffi; Martin, Daniel;
Fokas, Emmanouil; Rödel, Claus; Rödel, Franz; Balermpas, Panagiotis (2019). Merkel Cell Polyoma
Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With
Merkel Cell Carcinoma. Frontiers in Oncology, 9:20.
DOI: https://doi.org/10.3389/fonc.2019.00020
2
ORIGINAL RESEARCH
published: 24 January 2019
doi: 10.3389/fonc.2019.00020
Frontiers in Oncology | www.frontiersin.org 1 January 2019 | Volume 9 | Article 20
Edited by:
Peter Brossart,
Universität Bonn, Germany
Reviewed by:
Daniel Olive,
Aix Marseille Université, France
Graham Robert Leggatt,
The University of Queensland,
Australia
*Correspondence:
Panagiotis Balermpas
panagiotis.balermpas@usz.ch
†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Cancer Immunity and Immunotherapy,
a section of the journal
Frontiers in Oncology
Received: 19 October 2018
Accepted: 07 January 2019
Published: 24 January 2019
Citation:
von der Grün J, Winkelmann R,
Meissner M, Wieland U, Silling S,
Martin D, Fokas E, Rödel C, Rödel F
and Balermpas P (2019) Merkel Cell
Polyoma Viral Load and Intratumoral
CD8+ Lymphocyte Infiltration Predict
Overall Survival in Patients With Merkel
Cell Carcinoma. Front. Oncol. 9:20.
doi: 10.3389/fonc.2019.00020
Merkel Cell Polyoma Viral Load and
Intratumoral CD8+ Lymphocyte
Infiltration Predict Overall Survival in
Patients With Merkel Cell Carcinoma
Jens von der Grün 1†, Ria Winkelmann 2†, Markus Meissner 3, Ulrike Wieland 4, Steffi Silling 4,
Daniel Martin 1, Emmanouil Fokas 1,5,6, Claus Rödel 1,5,6, Franz Rödel 1,5,6 and
Panagiotis Balermpas 1,5,6,7*
1Department of Radiotherapy and Oncology, University of Frankfurt, Frankfurt, Germany, 2Dr. Senckenberg Institute
of Pathology, University of Frankfurt, Frankfurt, Germany, 3Department of Dermatology, University of Frankfurt, Frankfurt,
Germany, 4 Institute of Virology, National Reference Center for Papilloma and Polyomaviruses, University of Cologne, Cologne,
Germany, 5German Cancer Research Center (DKFZ), Heidelberg, Germany, 6German Cancer Consortium (DKTK) Partner
Site Frankfurt, Frankfurt, Germany, 7Department of Radiation Oncology, University Hospital Zürich, Zurich, Switzerland
Introduction: Merkel cell carcinoma (MCC) is linked to the presence of clonally
integrated Merkel cell polyomavirus (MCPyV) in up to 80% of the cases. The aim of
the study was to determine the prognostic value of baseline MCPyV viral load and
lymphocytic infiltration.
Methods: MCPyV DNA prevalence, integration status and viral load were determined
by specific quantitative real-time PCR in surgical specimens obtained from 49 patients
with MCC treated with (n = 22, 45%) or without postoperative radiotherapy (RT). CD8+
tumor infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) status
were assessed using immunohistochemistry. MCPyV characteristics and immunemarker
expression were correlated with clinicopathological factors and overall survival (OS).
Results: Median age at diagnosis was 74 (range, 42–100); 51% of the patients were
female. One-, three, and five-year OS rates were 83.8, 58.6, and 47.1%, respectively.
A positive MCPyV status was associated with female gender (p = 0.042). Tumor
localization (head/arms vs. trunk) positively correlated with PD-L1 status (p = 0.011) and
combined CD8/PD-L1 expression (p = 0.038). Overall CD8+ infiltration was inversely
associated with N-stage (p = 0.048). Stromal TILs correlated significantly with both
PD-L1 expression (p = 0.010) and N-stage (p = 0.037). A high viral load (>median)
was significantly associated with worse OS (p = 0.029) and high intratumoral CD8+
infiltration with improved OS for the entire cohort (p = 0.045).
Conclusion: These data provide important insight on the role of MCPy DNA viral load
and TILs in the context of PD-L1 in patients with Merkel cell carcinoma. Future clinical
studies should aim to explore the effect of PD-1/PD-L1 immune-checkpoint inhibitors in
combination with existing radiotherapy approaches.
Keywords: merkel cell carcinoma, polyomavirus (MCPyV), CD8+ tumor infiltrating lymphocytes, PD-L1,
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INTRODUCTION
Merkel cell carcinoma (MCC) is a rare neuroendocrine,
cutaneous malignancy with an incidence rate of 0.13 per 1,00,000
residents in Europe between 1995 and 2002 (1). Therapy consists
of surgery only (if N0), surgery followed inmost cases by adjuvant
radiotherapy (RT) or, more recently, by novel approaches,
including immune-checkpoint inhibitors (ICI) in metastatic
disease (2–4). The 5-year MCC-specific mortality rate is up to
46% (5, 6). MCC tumorigenesis is linked to the presence of
clonally integrated Merkel cell polyomavirus (MCPyV) in up to
80% of the cases, or mutagenesis from ultraviolet light (UV)
exposure for MCPyV-negative tumors, as well as advanced age
and immunosuppression (3, 7). MCPyV integrates into the host
cells genome and persistent expression of MCPyV T antigens is
required for MCC tumor cell survival (8). Immunosuppression
due to, e.g., organ transplantation or chronic lymphatic leukemia
significantly increases the risk for MCC, thus indicating a pivotal
role of the host immune system in tumorigenesis (7).
Although it has been reported that patients with high
intratumoral CD8+ and CD4+ lymphocyte infiltration show
better clinical outcome, including complete spontaneous tumor
regression (9–11), the majority of MCC tumors progress despite
the presence of T-cells priming MCPyV capsid proteins and
oncoproteins. MCC seems to be capable of escaping immune
response via down-regulation of major histocompatibility
complex class I (MHC-I), Toll-like Receptor 9 (TLR9), and
prevention of NF-kB translocation into the nucleus (8, 12).
Upregulation of programmed death ligand 1 (PD-L1) expression
in response to interferon-γ, released by CD8+ TILs as an
adaptive immune-resistance mechanism, can suppress local
effector T-cell function. ICI against the PD-1/PD-L1 axis have
shown promising results in the treatment of metastaticMCC, and
recently resulted in the approval of Avelumab (anti-PD-L1) by
the Food and Drug Administration (FDA) (4).
In this study we aimed to correlate MCPyV quantitative viral
load, CD8+ tumor infiltrating lymphocytes (TILs), and PD-L1
expression with clinicopathological characteristics and overall
survival (OS) in patients with MCC.
PATIENTS AND METHODS
Patients and Treatment
We retrospectively analyzed 49 patients treated for histologically-
proven MCC between June 2000 and September 2017 at
the Departments of Dermatology and/or Radiotherapy of the
University of Frankfurt, Germany. All patients underwent
physical examination and complete tumor excision. In case of
>cT1 or cN1 cM0, a sentinel lymph node biopsy (SLNB) was
performed, followed, in case of positive SLNB, by a regional
lymph node dissection and in most cases by adjuvant RT.
Depending on tumor site and volume, RTwas administered using
3D-conformal or intensity-modulated radiotherapy (IMRT, since
2010) utilizing photon or electron beams and energies ≥6MV.
RT-doses ranged between 20.0 and 70.0 Gray (Gy, median:
60.0Gy). All patients provided informed consent for sample and
clinical data collection. All procedures performed in this study
followed approval of our institutional ethics committee (No. 4/09
UCT-03-2017) and were in accordance with the standards of the
1964 Helsinki declaration and its later amendments.
Immunohistochemistry
Formalin fixed paraffin embedded (FFPE) tumor samples derived
from the Dr. Senckenberg Institute of Pathology, and the
Department of Dermatology, University of Frankfurt, were
subjected to an automatic staining procedure with standardized
DAKO EnVisionTM FLEX Peroxidase Blocking reagent (K8000,
DAKO, Hamburg, Germany) on a DAKO Autostainer Link 48
(DAKO). Antigen retrieval was performed by treatment of the
sections using an Epitope Retrieval Solution (Trilog, CellMarque,
Rocklin, CA) for 20min. Slides were stained with the primary
antibodies for either CD8 (1:100, clone C8/144B; Dako M7103)
or PD-L1 (1:50, clone E1L3N(R); Cell Signaling Technology) for
120min at room temperature. Next, dextran polymer conjugated
horseradish peroxidase and 3,3
′
-diamino-benzidine (DAB)
chromogen were used for visualization and hematoxylin solution
(Gill 3, Sigma Aldrich, Munich, Germany) for counterstaining.
Blinded samples were evaluated by two investigators (J.V. and
P.B.) without knowledge of the clinicopathologic and clinical
data as described before (13, 14). In cases of discrepancy, a final
decision wasmade after additional examination of the specimens.
The expression of CD8+ TILs was scored semi-quantitatively
via measurement of cell density. Scoring was as follows: for the
intra-epithelial, invasive front and stromal compartments: (i) no,
or sporadic cells; (ii) moderate numbers of cells; (iii) abundant
occurrence of cells; and (iv) highly abundant occurrence of cells.
The total score was calculated by adding the separate scores from
all three compartments (range, 3–12). Themedian score was used
as cut-off to classify patients into two groups: low (<median) or
high (≥median) CD8+ infiltration. PD-L1 tumor expression as
evaluated for each sample in different representative fields and
expression in >1% of the tumor cells were considered positive as
reported before (15).
MCPyV Detection and DNA Load
Determination
Determination of MCPyV DNA load and MCPyV integration
status were performed on five 10µm FFPE sections using a
LightCycler 480 Real Time PCR System (Roche, Mannheim,
Germany) as described previously (16, 17). Briefly, viral DNA
load was determined using MCPyV-specific LT3-primers and
a locked nucleic acid probe binding to the N-terminal part of
the large T-antigen gene (18). MCPyV DNA load was expressed
as MCPyV DNA copies per betaglobin-gene copy (17). The
integration status of the MCPyV DNA into the cellular host
genome was assessed with a real-time PCR-based MCPyV T-
antigen gene C-terminus deletion assay as described before (16).
For statistical analysis, a non-detectable viral DNA load was
defined as 0 and the median was calculated for the entire cohort
(n= 48).
Statistical Analysis
The association of MCPyV, CD8+ infiltration and PD-L1
expression with clinicopathological characteristics was assessed
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using Pearson’s Chi-squared test for categorical variables and
Mann-Whitney U test for continuous variables. The clinical
outcome measure was overall survival (OS) as defined from the
time-point of histologically confirmed diagnosis ofMCC to death
from any cause. Differences in OS between groups were plotted
using the Kaplan–Meier method and assessed using the Log-
rank test (Mantel-Cox; SPSS 25). A p < 0.05 was considered as
significant.
RESULTS
Patients and Tumor Characteristics
From a total of 49 patients, 25 (51.0%) were female. Median
age at diagnosis was 74 (range, 42–100) years. The head was
the main tumor site (45.5%), followed by arms (34.0%), and
body trunk (20.5%). A total of 54.5% of the patients had positive
lymph nodes, and 44.9% received adjuvant RT. Concerning
the MCPyV-DNA status, 1 MCC was not evaluable due to
low cellularity (betaglobin-gene copy number < 10), 38 of the
remaining 48 biopsies were MCPyV-DNA positive (79.2%), and
10 MCC (20.8%) were MCPyV-negative. The median viral DNA
load for the entire cohort (n = 48) was 0.745 (interquartile
range 0.007–4.448;mean 7.072; range 0.000–157.007). Integrated,
C-terminally deleted MCPyV-DNA was found in 22.9% of all
patients (11/48), episomal or full-length integratedMCPyV-DNA
in 33.3% of all patients (16/48), and in 22.9% of the entire
cohort (11/48) the integration status could not be evaluated or
was negative (20,8%, 10/48). Patient characteristics are given in
Table 1.
Clinicopathological Characteristics and
Their Association With MCPyV Status, CD8
Infiltration, and PD-L1 Expression
For CD8+ TILs, the median score was used as cut-off to
dichotomize between low and high infiltration, whereas PD-
L1+ expression in >1% of the tumor cells was considered
positive (Figure 1). Tumor localization (head/arms vs.
trunk) positively correlated with PD-L1 status (p = 0.011,
Table 2) and combined CD8/PD-L1 expression (p = 0.038,
Supplementary Table 2). Overall CD8+ infiltration was
inversely associated with N-stage (p = 0.048, Table 2). A high
stromal CD8+ infiltration was associated with PD-L1 positivity
(p = 0.010) and N-stage (p = 0.037, Table 3). Further, a
positive MCPyV status and high viral DNA load were associated
with female gender (p = 0.042 and 0.021, respectively)
(Table 2 and Supplementary Table 1).
Overall Survival and Correlation With
MCPyV DNA Load, CD8, and PD-L1
One-, three-, and five-year OS rates were 83.8, 58.6, and
47.1%, respectively (Figure 2). Cumulative (p = 0.078)
and stromal (p = 0.279) expression of CD8+ TILs
were not associated with OS, whereas elevated levels of
intratumoral CD8+ cells correlated significantly with
superior OS for the entire cohort (p = 0.045, Figure 2).
High levels of DNA viral load (>median) were significantly
TABLE 1 | Patients characteristics.
Clinical characteristics n (%)
Total (n = 49)
GENDER
Male 24 (49.0)
Female 25 (51.0)
Age, median (range) 74 (42–100)
TUMOR LOCALIZATION
Head 20 (45.5)
Arm 15 (34.0)
Body trunk 9 (20.5)
Missing values 5
cN-CATEGORY
cN0 15 (45.5)
cN+ 18 (54.5)
Missing values 16
CD8 SCORE‡
<median 25 (51.0)
≥median 24 (49.0)
PD-L1*
≤1% 21 (42.9)
>1% 28 (57.1)
MCPyV DNA STATUS
Positive 38 (79.2)
Negative 10 (20.8)
Not assessable 1
VIRAL INTEGRATION STATUS
Integrated,C-terminally deleted 11 (22.9%)
Episomal or full-length integrated 16 (33.3%)
Integration status not assessable 11 (22.9%)
MCPyV-negative 10 (20.8%)
Missing values 1
RADIOTHERAPY
Yes 22 (44.9)
No 27 (55.1)
MCPyV, Merkel Cell Polyomavirus. *% PD-L1+ tumor cells. ‡CD8+ tumor infiltration.
related to a worse OS (p = 0.029, Figure 3). The
association remained significant after exclusion of cases
that lack detectable viral DNA (p = 0.034 for n = 38,
Supplementary Figure 1). PD-L1-positivity did not correlate
with OS (p= 0.966).
DISCUSSION
MCC is an aggressive disease with various options
of the malignant cells to avoid immune response.
Accumulating evidence indicates a direct association of
higher “immunogenicity” and response to RT in MCC (19),
and other virus-associated malignancies, including HPV-16/18
induced oropharyngeal and anal carcinoma (13, 20, 21). A recent
investigation in 805 patients with MCC indicated a significantly
impaired efficacy of RT in terms of local tumor control and
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FIGURE 1 | Immunohistochemical staining of CD8 and PD-L1. (A) CD8: low: <median score of 5, (B) high: ≥median score of 5 (range 3–12); (C) PD-L1: ≤1%
positive tumor cells (low) and (D) >1% positive tumor cells (high).
recurrence-free survival for patients with immunosuppression
(22). Further understanding of tumor driving mechanisms
may lead to new strategies facing this rare tumor
entity.
In the present study, we quantitatively evaluated the
prevalence, viral load, and genomic integration into the host
DNA of MCPyV in a cohort of MCC-patients and correlated
these parameters with OS, PD-L1 status, and CD8+ lymphocyte
infiltration. To the best of our knowledge, this is the first
study investigating the relationship between MCPyV viral
load and survival (9, 23). Vandeven et al. could demonstrate
that MCC of unknown primary (MCUP) was associated with
higher levels of MCPyV-antibodies and higher mutational load,
as surrogate parameters for immunogenicity, and correlated
with improved survival when compared to patients with
identified primary tumors (24). Additionally, other authors have
reported a positive correlation of a high antibody titer with
MCPyV status and OS for classical MCC (18, 25, 26). These
data provide a strong rationale for a virus-triggered effective
immune-activation as a pivotal mechanism underlying tumor
elimination.
Intriguingly, a high viral load correlated with worse OS in
our cohort while tumors with a lower load or lack of viral DNA
displayed increased OS. MCPyV negative tumors are mainly
considered to be induced by ultraviolet radiation and present
a high mutational burden in general and more specifically
high incidence of p53 (75%) and Rb mutations (67%) (27,
28). Emerging evidence shows a clear association of mutational
load and prognosis for almost any malignancy, a phenomenon
associated with the increased immunogenicity of such tumors
(29). The percentage of non-virally induced tumors in our cohort
is in accordance with the literature (28, 30). These extensively—
mutated cases could have an even better outcome compared
to MCPyV-driven tumors, such biasing the survival-analysis.
Moreover, a less favorable outcome for MCPyV negative tumors
has been reported before (25, 31). However, the significance
for the correlation of high viral load and OS still remained
after exclusion of cases without any detectable viral DNA. A
possible reason for the impaired survival of patients with high
viral-load is a missing or ineffective immune response due to
immunosuppression or various cancer- and microenvironment-
associated mechanisms, including alteration of regulatory T cell
function and activation of the PD-1/PD-L1 axis (32, 33). Notably,
similar findings have been reported for Epstein-Barr-Virus
(EBV) associated nasopharyngeal cancer, where a high EBV-
DNA load in the plasma correlated with an impaired outcome
(34, 35).
Until the advent of ICI, chemotherapy was standard of
care in the treatment of advanced MCC. First-line platinum-
based chemotherapy combined with Etoposide showed overall
response rates (ORR) of 31–55% with shorter progression-
free survival than those recently reported for anti-PD-1/PD-
L1 ICI (3). In a recent phase 2 trial the anti-PD-L1 antibody
Avelumab was applied to 88 patients with stage IV MCC
that had progressed after chemotherapy. Objective response
was reached in 32% of the patients indicating superiority of
novel immune-modulating therapies (2). These findings resulted
in the first approval of a checkpoint inhibitor in MCC (4).
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TABLE 2 | Clinicopathological characteristics and their association with MCPyV status and immune microenvironment.
Clinico-pathological
characteristics
MCPyV status, n (%) p† CD8‡, n (%) p† PD-L1*, n (%) p†
Negative# Positive <Median ≥Median ≤1% >1%
N-STAGE (n = 33)
Negative 7
(46.7)
8
(53.3)
4
(26.7)
11
(73.3)
7
(46.7)
8
(53.3)
Positive 7
(38.9)
11
(61.1)
0.653 11
(61.1)
7
(38.9)
0.048 7
(38.9)
11
(61.1)
0.653
TUMOR LOCALIZATION (n = 45)
Head or arms 16
(45.7)
19
(54.3)
20
(57.1)
15
(42.9)
16
(45.7)
19
(54.3)
Other 3
(33.3)
6
(66.7)
0.504 3
(22.2)
7
(77.8)
0.062 0
(0)
9
(100.0)
0.011
PD-L1* (n = 49)
≤1% 9
(45.0)
11
(55.0)
14
(66.7)
7
(33.3)
>1% 12
(42.9)
16
(57.1)
0.883 11
(39.3)
17
(60.7)
0.058
CD8‡(n = 49)
<median 11
(45.8)
13
(54.2)
14
(56.0)
11
(44.0)
≥median 10
(41.7)
14
(58.3)
0.771 7
(29.2)
17
(70.8)
0.058
MCPyV STATUS (n = 48)
Negative# 7
(70.0)
3
(30.0)
4
(40.0)
6
(60.0)
Positive 17
(44.7)
21
(55.3)
0.155 16
(42.1)
22
(57.9)
0.503
GENDER (n = 49)
Male 14
(58.3)
10
(41.7)
12
(50.0)
12
(50.0)
9
(37.5)
15
(62.5)
Female 7
(29.2)
17
(70.8)
0.042 13
(52.0)
12
(48.0)
0.889 12
(48.0)
13
(52.0)
0.458
MCPyV, Merkel Cell Polyomavirus; PD-L1,Programmed cell death ligand 1. *% PD-L1+ tumor cells. ‡CD8+ tumor infiltration, overall score. #defined as negative or not assessable
†
p-values according to Pearson’s Chi-squared test and calculated after exclusion of missing values. Significant results have been marked with bold.
TABLE 3 | PD-L1 and N-stage and their association with stromal CD8 infiltration.
Clinico-pathological
characteristics
Stromal CD8+ infiltration, n (%) p†
<Median ≥Median
PD-L1* (n = 49)
≤1% 12 (57.1) 9 (42.9)
>1% 6 (21.4) 22 (78.6) 0.010
N-STAGE (n = 33)
Negative 3 (20.0) 12 (80.0)
Positive 10 (55.6) 8 (44.4) 0.037
PD-L1,Programmed cell death ligand 1. *% PD-L1+ tumor cells.
†
p-values according to
Pearson’s Chi-squared test and calculated after exclusion of missing values. Significant
results have been marked with bold.
Other studies investigating anti-PD-1 antibodies Nivolumab
(+/- prior chemotherapy, recruiting) and Pembrolizumab (no
prior chemotherapy) reported ORR of 68 and 56%, respectively
(36, 37). In our cohort, PD-L1 status, however, was not associated
with altered outcome, suggesting that this marker may be
predictive for response to targeted therapy but not prognostic.
Regarding infiltration with CD8-positive cytotoxic
lymphocytes, we identified a significant correlation between
intratumoral CD8+ infiltration and OS, and a significant
inverse correlation with nodal-stage (a widely accepted negative
prognosticator for MCC). Notably, N+ disease in our cohort
occurred in 54.5% of the cases while literature reports on 37%
(7), a fact attributed to selection bias, as many of the patients
included here were referred to the department of radiotherapy.
In a larger study by Paulson et al., both clinical stage and
CD8-infiltration were of prognostic relevance (10). More
recent analyses of larger numbers of samples seem to confirm
these assumptions (9, 38, 39) and the same was true when the
specificity of T cells for MCPyV was taken to account (40).
Interestingly, we did not observe any significant correlation
between total tumor CD8-infiltration, PD-L1 expression, and
viral load, indicating that mechanisms other than viral infection
(e.g., ultraviolet radiation-induced mutations) may contribute
to immune response. On the contrary, stromal infiltration
with CD8+ TILs significantly correlated with both PD-L1 and
Frontiers in Oncology | www.frontiersin.org 5 January 2019 | Volume 9 | Article 20
von der Grün et al. Polyoma-Virus and Lymphocytes in Merkel Cell Carcinoma
FIGURE 2 | Overall survival stratified by CD8 immune infiltration. (A) Overall survival, (B) Overall survival stratified by CD8 median score, (C) Overall survival stratified
by CD8 intratumoral median score, (D) Overall survival stratified by CD8 stromal median score; p-values according to log-rank test (Mantel Cox).
FIGURE 3 | Patients outcome and correlation with MCPyV DNA load and PD-L1. (A) Overall survival stratified by MCPyV DNA median load (n = 48), (B) Overall
survival stratified by PD-L1 status; MCPyV, Merkel Cell Polyomavirus; p-values according to log-rank test (Mantel Cox).
MCPyV. This argues for a locally restricted, viral antigene-driven
immune response that failed to control the tumor in a PD-L1
dependent manner, that could be potentially reversed by ICI (41).
With respect to the correlation of MCPyV status/viral DNA
load with clinical and epidemiological parameters, the most
important finding in the present cohort was a significant
correlation with female gender although the limited number of
patients in our study does not allow definite conclusions yet.
In line with that, the higher prevalence of MCPyV in female
patients has been reported before, but a possible association
with tumor site remains controversial (18, 42, 43). There is
no molecular explanation readily available for the increased
prevalence in women. A putative reason, however, may be
the observation that tumors in females were diagnosed more
frequently in older patients (median age females 77.0 years vs.
median age males 70.5). In line with that, Álvarez-Argüelles
et al. recently speculated that there may an immunosuppressive
component due to age contributing to the sex effect in MCPyV
detection demonstrated in their analyses and in our study
(44). Unfortunately we could not prove an association of
age and viral load in our data. Another possible explanation
could be a higher UV-exposure as casual factor in the male
population. Yet there exist no data to undermine this speculation,
although a viral etiology has been associated with female sex
by many authors (18, 42, 43). Interestingly, male sex, and
advanced age were associated with worse prognosis in the
literature (7).
We acknowledge that the retrospective evaluation and the
small number of patients is a limitation of our study. A potential
calculation bias cannot be excluded. However, this is the first
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study quantitatively assessing and correlating the MCPyV viral
load to clinical parameters that warrant validation in larger,
independent cohorts with long-term follow-up.
CONCLUSION
These data provide important insight on the crucial role of
MCPyV DNA load and TILs, in the context of PD-L1, in patients
with MCC. We consider our findings on a correlation of PDL-
1 with tumor localization and CD8+ Tils and a prognostic
relevance of intratumoral CD8+ T cell infiltration to be in
favor of a future checkpoint immunotherapy in MCC. Moreover,
there is growing pre-clinical and clinical evidence on an
additional improvement of the effects of checkpoint-inhibition
by synergistic effects of radiation therapy (45, 46). Consequently,
future clinical studies should aim to explore the effect of PD-
1/PD-L1 immune-checkpoint inhibitors in combination with
existing radiotherapy approaches.
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